The AAP policy statement from the Committee on Infectious Diseases, “Recommendations for Prevention and Control of Influenza, 2017-2018,” (Pediatrics 2017;140(4): e20172550) has been updated with information regarding a new antiviral medication, peramivir.
The online statement been updated with the following changes:
On page 8, Key point No. 12 now reads “Intravenous peramivir (Rapivab [BioCryst Pharmaceuticals, Durham, NC]), a third NAI, was approved in September 2017 for use as treatment for acute uncomplicated influenza in nonhospitalized children 2 years and older.”
On page 13, Table 6 has been updated to include dosage information for peramivir as well as a footnote describing details of the medication, and routes of administration were added for each medication.
On page 13, the section on Use of Antiviral Medications has been updated to peramivir as an option for children.
On page 19, the Resource by Bradley et al, which had been “in press,” has been updated with its full citation.